Efficacy of nafamostat mesylate in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis of randomized controlled trials.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Dec 2023
27 Dec 2023
Historique:
received:
08
03
2023
accepted:
16
12
2023
medline:
29
12
2023
pubmed:
29
12
2023
entrez:
28
12
2023
Statut:
epublish
Résumé
We conducted a systematic review and meta-analysis to evaluate the effect of nafamostat on the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PubMed, Web of Science, and Ichushi Web were searched for randomized controlled trials (RCTs) using nafamostat to prevent PEP. In subgroup analyses, we studied the preventive effects of nafamostat according to the severity of PEP, risk category, and dose. A random-effects model was adopted; heterogeneity between studies was examined using the chi-squared test and I
Identifiants
pubmed: 38155200
doi: 10.1038/s41598-023-50181-6
pii: 10.1038/s41598-023-50181-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23012Informations de copyright
© 2023. The Author(s).
Références
Freeman, M. L. et al. Risk factors for post-ERCP pancreatitis: A prospective, multicenter study. Gastrointest. Endosc. 54, 425–434 (2001).
doi: 10.1067/mge.2001.117550
pubmed: 11577302
Andriulli, A. et al. Incidence rates of post-ERCP complications: A systematic survey of prospective studies. Am. J. Gastroenterol. 102, 1781–1788 (2007).
doi: 10.1111/j.1572-0241.2007.01279.x
pubmed: 17509029
Kochar, B. et al. Incidence, severity, and mortality of post-ERCP pancreatitis: A systematic review by using randomized, controlled trials. Gastrointest. Endosc. 81, 143–149 (2015).
doi: 10.1016/j.gie.2014.06.045
pubmed: 25088919
Serrano, J. P. R. et al. Nonsteroidal anti-inflammatory drugs versus placebo for post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis. Endosc. Int. Open 7, E477 (2019).
doi: 10.1055/a-0862-0215
pubmed: 30957004
pmcid: 6445649
Ding, J. et al. Glyceryl trinitrate for prevention of post-ERCP pancreatitis and improve the rate of cannulation: A meta-analysis of prospective, randomized, controlled trials. PLoS One 8, e75645 (2013).
doi: 10.1371/journal.pone.0075645
pubmed: 24098392
pmcid: 3787965
Yu, G. et al. Nafamostat mesilate for prevention of post-ERCP pancreatitis: A meta-analysis of prospective, randomized, controlled trials. Pancreas 44, 561–569 (2015).
doi: 10.1097/MPA.0000000000000310
pubmed: 25822153
Takada, T. et al. JPN clinical practice guidelines 2021 with easy-to-understand explanations for the management of acute pancreatitis. J. Hepatobiliary Pancreat. Sci. 29, 1057–1083 (2022).
doi: 10.1002/jhbp.1146
pubmed: 35388634
Buxbaum, J. L. et al. American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: Summary and recommendations. Gastrointest. Endosc. 97, 153–162 (2023).
doi: 10.1016/j.gie.2022.10.005
pubmed: 36517310
Dumonceau, J. M. et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 52, 127–149 (2020).
doi: 10.1055/a-1075-4080
pubmed: 31863440
Zhou, Y. et al. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat. Biophys J. 121, 3940–3949 (2022).
doi: 10.1016/j.bpj.2022.08.034
pubmed: 36039386
pmcid: 9674978
Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 28, 366 (2019).
Kaneda, Y. Investigation of freely-availavle easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant. 48, 452–458 (2013).
doi: 10.1038/bmt.2012.244
Higgins, J. P. T., Green, S. & Cochrane Collaboration. Cochrane Handbook for Systematic Reviews on Interventions. (Wiley-Blackwell, 2008).
Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 372, n71 (2021).
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Yuhara, H. et al. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: Protease inhibitors and NSAIDs in a meta-analysis. J. Gastroenterol. 49, 388–399 (2014).
doi: 10.1007/s00535-013-0834-x
pubmed: 23720090
Yamashita, Y. et al. Efficacy of 20 mg/day of nafamostat mesylate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis. Gastroenterol. Endosc. 55, 3548–3554 (2013).
Sherman, S. et al. Stent-induced pancreatic ductal and parenchymal changes: Correlation of endoscopic ultrasound with ERCP. Gastrointest. Endosc. 44, 276–282 (1996).
doi: 10.1016/S0016-5107(96)70164-5
pubmed: 8885346
Smith, M. T. et al. Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest. Endosc. 44, 268–275 (1996).
doi: 10.1016/S0016-5107(96)70163-3
pubmed: 8885345
Forsmark, C. E., Baillie, J., AGA Institute Clinical Practice and Economics Committee; AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis. Gastroenterology 132, 2022–2044 (2007).
Lerch, M. M. et al. Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum. Gastroenterology. 104, 853–861 (1993).
doi: 10.1016/0016-5085(93)91022-A
pubmed: 7680018
Imaizumi, H. et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 28, 369–373 (2004).
doi: 10.1097/00006676-200405000-00003
pubmed: 15097852
Shimosegawa, T. et al. Consensus for initial treatment of acute pancreatitis, revised 3rd edition. Pancreas 26, 651–683 (2011).
doi: 10.2958/suizo.26.651
Munjal, A. & Allam, A. E. Indomethacin (StatPearls, 2023).
Hernández-Mitre, M. P. et al. Nafamostat mesylate for treatment of COVID-19 in hospitalised patients: A structured, narrative review. Clin. Pharmacokinet. 61, 1331–1343 (2022).
doi: 10.1007/s40262-022-01170-x
pubmed: 36040613
pmcid: 9425784
Hiroki, A. et al. Risk of hyperkalemia caused by nafamostat mesilate in geriatric patients. J. Pharm. Health Care Sci. 46, 561–566 (2020).
doi: 10.5649/jjphcs.46.561
Matsumoto, T. et al. Nafamostat mesylate is not effective in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. Dig. Dis. Sci. 66, 4475–4484 (2021).
doi: 10.1007/s10620-020-06782-6
pubmed: 33495919
Ohuchida, J. et al. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 44, 415–421 (2015).
doi: 10.1097/MPA.0000000000000278
pubmed: 25479585
Park, J. Y. et al. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: A prospective, randomized trial. Pancreatology 14, 263–267 (2014).
doi: 10.1016/j.pan.2014.03.022
pubmed: 25062874
Kwon, Y. H. et al. Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?. Korean J. Gastroenterol. 59, 232–238 (2012).
doi: 10.4166/kjg.2012.59.3.232
pubmed: 22460572
Park, K. T. et al. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?. Pancreas. 40, 1215–1219 (2011).
doi: 10.1097/MPA.0b013e31822116d5
pubmed: 21775918
Yoo, K. S. et al. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized, double-blind, controlled trial. Pancreas 40, 181–186 (2022).
doi: 10.1097/MPA.0b013e3181f94d46
Moon, S. W. et al. Prophylactic effect of nafamostat on post ERCP pancreatitis: Prospective, randomized, placebo-controlled trial. J. Gastroenterol. Hepatol. 25, A65 (2010).
Choi, C. W. et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest. Endosc. 69, e11–e18 (2009).
doi: 10.1016/j.gie.2008.10.046
pubmed: 19327467
Fukumoto, K. et al. On the inhibitory effects of a protease-inhibiting agent, FUT-175, on the escape of activated pancreatic enzymes after the endoscopic retrograde cholangio-pancreatography, -especially on the activities of amylase, trypsin, elastase 1, and lipase-. Basic Pharmacol. Ther. 15, 793–803 (1987).